George Siber, executive chairman of Genocea's board, said: "In Chip [Clark]'s short time at Genocea, he has proven himself to be a tremendous asset to the company" and the company said he "played a critical role in closing the company's $35m round of series B financing announced last month".
Genocea Biosciences, a US-based vaccine development company backed by GlaxoSmithkline’s (GSK) corporate venturing division, has promoted Chip Clark to be executive president six months after he joined the company as chief business officer. He replaces Staph Leavenworth Bakali.
Clark previously had been chief business officer at Vanda Pharmaceuticals, been a principal at Care Capital, a venture capital firm that invested in Vanda, and spent 10 years at SmithKline Beecham (now part of GSK).
George Siber, executive chairman of Genocea’s…
